Hepatitis C Virus RNA Elimination and Development of Resistance in Replicon Cells Treated with BMS-790052
Open Access
- 1 March 2012
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (3) , 1350-1358
Abstract
BMS-790052, a first-in-class hepatitis C virus (HCV) replication complex inhibitor, targeting nonstructural protein 5A (NS5A), displays picomolar to nanomolar potency against genotypes 1 to 5. This exceptional potency translated into robust anti-HCV activity in clinical studies with HCV genotype 1-infected subjects. To date, all BMS-790052-associated resistance mutations have mapped to the N-terminal region of NS5A. To further characterize the antiviral activity of BMS-790052, HCV replicon elimination and colony formation assays were performed. Replicon was cleared from genotype 1a and 1b replicon cells in a time- and dose-dependent manner. Elimination of the genotype 1a replicon required longer treatment durations and higher concentrations of BMS-790052 than those for the genotype1b replicon. Single amino acid substitutions that conferred relatively low levels of resistance were observed at early time points and at low doses. Higher doses and longer treatment durations yielded mutations that conferred greater levels of resistance, including linked amino acid substitutions. Replicon cells that survived inhibitor treatment remained fully sensitivity to pegylated alpha interferon (pegIFN-α) and other HCV inhibitors. Moreover, genotype 1a replicon elimination was markedly enhanced when pegIFN-α and BMS-790052 were combined. Resistant variants observed in this study were very similar to those observed in a multiple ascending dose (MAD) monotherapy trial of BMS-790052, validating replicon elimination studies as a model to predict clinical resistance. Insights gained from the in vitro anti-HCV activity and resistance profiles of BMS-790052 will be used to help guide the clinical development of this novel HCV inhibitor.Keywords
This publication has 21 references indexed in Scilit:
- Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1Hepatology, 2010
- The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2008
- Epidemiology of hepatitis C virus infectionWorld Journal of Gastroenterology, 2007
- euHCVdb: the European hepatitis C virus databaseNucleic Acids Research, 2006
- Development of a Cell-Based High-Throughput Specificity Screen Using a Hepatitis C Virus-Bovine Viral Diarrhea Virus Dual Replicon AssayAntimicrobial Agents and Chemotherapy, 2005
- Replication-Competent Chimeric Hepatitis C Virus Subgenomic RepliconsIntervirology, 2005
- Genetic variation and dynamics of hepatitis C virus replicons in long-term cell cultureJournal of General Virology, 2005
- Genetic diversity and evolution of hepatitis C virus – 15 years onJournal of General Virology, 2004
- Efficient Initiation of HCV RNA Replication in Cell CultureScience, 2000
- Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell LineScience, 1999